Intelligence Feed event · Equity · 2026-10-07

    Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout

    Direct answer

    Oculis confirmed that Chief Executive Officer Riad Sherif will outline clinical progress on Licaminlimab at the Eyecelerator event during the American Academy of Ophthalmology (AAO) 2026 meeting on October 8. Licaminlimab is an investigational topical anti-TNF alpha candidate developed for TNFR1-mediated dry eye disease. Management reiterated that topline efficacy data from the ongoing PREDICT-1 registrational trial will be reported around the end of 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-aao-2026-ahead-of-year-end-predict-1-readout-340352

    EQUITY
    Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout
    Oculis confirmed that Chief Executive Officer Riad Sherif will outline clinical progress on Licaminlimab at the Eyecelerator event during the American Academy of Ophthalmology (AAO) 2026 meeting on October 8. Licaminlimab is an investigational topical anti-TNF alpha candidate developed for TNFR1-mediated dry eye disease. Management reiterated that topline efficacy data from the ongoing PREDICT-1 registrational trial will be reported around the end of 2026.
    OCS
    Impact
    59
    OCT 7
    SIG
    88%
    OCS
    Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout
    Oculis confirmed that Chief Executive Officer Riad Sherif will outline clinical progress on Licaminlimab at the Eyecelerator event during the American Academy of Ophthalmology (AAO) 2026 meeting on October 8. Licaminlimab is an investigational topical anti-TNF alpha candidate developed for TNFR1-mediated dry eye disease. Management reiterated that topline efficacy data from the ongoing PREDICT-1 registrational trial will be reported around the end of 2026.
    → Clinical progress toward year-end registrational phase data triggers speculative positioning in OCS equity ahead of binary trial efficacy readout.
    Impact
    Oculis confirmed that Chief Executive Officer Riad Sherif will outline clinical progress on Licaminlimab at the Eyecelerator event during the American Academy of Ophthalmology (AAO) 2026 meeting on October 8. Licaminlimab is an investigational topical anti-TNF alpha candidate developed for TNFR1-mediated dry eye disease. Management reiterated that topline efficacy data from the ongoing PREDICT-1 registrational trial will be reported around the end of 2026.
    Affected
    OCS
    Transmission
    Clinical progress toward year-end registrational phase data triggers speculative positioning in OCS equity ahead of binary trial efficacy readout.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech registrational trial catalyst progressionUp1-3mOculis confirmed PREDICT-1 registrational trial topline readout on track for year-end 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month